Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karolinska Development AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karolinska Development AB, Medical Devices Deals, 2012 to YTD 2018 10
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karolinska Development AB, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Umecrine Cognition Raises USD2.5 Million in Venture Financing 14
Umecrine Cognition Raises USD4.8 Million in Venture Financing 15
Dilafor Raises USD6 Million in Venture Financing 16
Aprea Therapeutics Raises USD52 Million in Series B Financing 17
Umecrine Cognition Raises Funds in Private Financing Round 18
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 19
Forendo Pharma Raises Funds In First Round Of Venture Financing 21
GliGene Raises US$1 Million In First Round Of Financing 22
ProNoxis Raises US$0.6 Million In Venture Financing 23
Equity Offering 24
Pharmanest to Raise Funds through Private Placement of Shares 24
Xspray Pharma Raises USD1.3 Million in IPO 25
Modus Therapeutics Raises USD3.6 Million in Financing 26
Karolinska Development Raises USD8.5 Million in Private Placement of Series B Shares 27
Acquisition 28
Karolinska Development Divests its Remaining Stake in BioArctic for USD1.4 Million 28
Karolinska Development Divests its Stake in Lipidor 29
Karolinska Development Divests Certain Stake in BioArctic for USD4 Million 30
Karolinska Development Sells its Stake in Xspray Pharma for USD1.6 Million 31
KDev Investments Sells Stake in Inhalation Sciences 32
Ostersjostiftelsen Consortium to Acquire Stake in Athera Biotechnologies from Karolinska Development 33
Ostersjostiftelsen and Recipharm Venture Acquire Stake in XSpray Microparticles 35
Ostersjostiftelsen, Recipharm Venture and Praktikerinvest Acquire Stake in Pharmanest from Karolinska Development 36
Ostersjostiftelsen Acquires Stake in Axelar from Karolinska Development 37
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 38
Redoxis Acquires Remaining 54% Stake In ProNoxis From Karolinska And LU Bio 41
Karolinska Development AB – Key Competitors 42
Karolinska Development AB – Key Employees 43
Karolinska Development AB – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 44
Recent Developments 45
Financial Announcements 45
Aug 16, 2018: Karolinska Development: Interim Report January – June 2018 45
Apr 25, 2018: Karolinska Development: Interim Report January – March 2018 47
Feb 15, 2018: Karolinska Development: Q4 and 2017 Year-End Report – January-December 48
Oct 31, 2017: Karolinska Development Publishes Interim Report (January – September 2017) And Reports A Positive Result For The Third Quarter 50
Aug 29, 2017: Karolinska Development: Interim Report – January-June 2017 51
May 16, 2017: Karolinska Development: Interim Report – January-March 2017 52
Feb 28, 2017: Karolinska Development Q4 net loss decreases 53
Corporate Communications 54
May 21, 2018: Pharmanest Appoints Helena Jansson As Chief Executive Officer 54
Mar 15, 2018: Karolinska Development’s portfolio company Modus Therapeutics appoints a new Chief Medical Officer 55
Dec 29, 2017: Karolinska Development’s Chairman of the Board resigns from his position 56
Oct 31, 2017: Changes in the Board of Directors at Karolinska Development 57
Oct 12, 2017: First day of trading in Karolinska Development’s portfolio company BioArctic’s shares on Nasdaq Stockholm 58
Sep 14, 2017: Karolinska Developments’s portfolio company Modus Therapeutics recruits new Chief Medical Officer 59
Sep 13, 2017: Karolinska Development’s Portfolio Company BioArctic Intends to list on Nasdaq Stockholm 60
Aug 29, 2017: Karolinska Development Appoints Fredrik Jarrsten as Chief Financial Officer 61
Aug 25, 2017: Karolinska Development Notes the Planned Listing of Xspray on Nasdaq First North 62
Apr 24, 2017: Karolinska Development company Modus Therapeutics announces appointment of Ellen K. Donnelly, Ph.D. as CEO 63
Apr 20, 2017: Karolinska Development announces Chairman Bo Jesper Hansen and CEO Jim Van heusden’s decision to Step Down, and the promotion of Viktor Drvota to CEO 64
Apr 20, 2017: Karolinska Development announces board changes 65
Mar 01, 2017: Karolinska Development names deputy CEO 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
Karolinska Development AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karolinska Development AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karolinska Development AB, Deals By Therapy Area, 2012 to YTD 2018 9
Karolinska Development AB, Medical Devices Deals, 2012 to YTD 2018 10
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Umecrine Cognition Raises USD2.5 Million in Venture Financing 14
Umecrine Cognition Raises USD4.8 Million in Venture Financing 15
Dilafor Raises USD6 Million in Venture Financing 16
Aprea Therapeutics Raises USD52 Million in Series B Financing 17
Umecrine Cognition Raises Funds in Private Financing Round 18
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 19
Forendo Pharma Raises Funds In First Round Of Venture Financing 21
GliGene Raises US$1 Million In First Round Of Financing 22
ProNoxis Raises US$0.6 Million In Venture Financing 23
Pharmanest to Raise Funds through Private Placement of Shares 24
Xspray Pharma Raises USD1.3 Million in IPO 25
Modus Therapeutics Raises USD3.6 Million in Financing 26
Karolinska Development Raises USD8.5 Million in Private Placement of Series B Shares 27
Karolinska Development Divests its Remaining Stake in BioArctic for USD1.4 Million 28
Karolinska Development Divests its Stake in Lipidor 29
Karolinska Development Divests Certain Stake in BioArctic for USD4 Million 30
Karolinska Development Sells its Stake in Xspray Pharma for USD1.6 Million 31
KDev Investments Sells Stake in Inhalation Sciences 32
Ostersjostiftelsen Consortium to Acquire Stake in Athera Biotechnologies from Karolinska Development 33
Ostersjostiftelsen and Recipharm Venture Acquire Stake in XSpray Microparticles 35
Ostersjostiftelsen, Recipharm Venture and Praktikerinvest Acquire Stake in Pharmanest from Karolinska Development 36
Ostersjostiftelsen Acquires Stake in Axelar from Karolinska Development 37
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 38
Redoxis Acquires Remaining 54% Stake In ProNoxis From Karolinska And LU Bio 41
Karolinska Development AB, Key Competitors 42
Karolinska Development AB, Key Employees 43
Karolinska Development AB, Subsidiaries 44
Karolinska Development AB, Joint Venture 44
List of Figures
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karolinska Development AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karolinska Development AB, Medical Devices Deals, 2012 to YTD 2018 10